Post-approval studies (Phase 4)Study completedNCT02798211
What this trial is testing
Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo
Who this might be right for
Psoriatic Arthritis
Novartis Pharmaceuticals 258